Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Filings Soon As Biogen Snaps Up Ionis' Antisense Treatment

Executive Summary

Promising top-line Phase III data have prompted Biogen to exercise an option to develop and commercialize Ionis's novel antisense treatment nusinersen for infantile-onset spinal muscular atrophy; filings are due shortly.

Advertisement

Related Content

Biogen/Ionis’s Spinraza Approved; Second Antisense Drug For Neurodegeneration In 2016
Biogen/Ionis’ Spinraza Data Shows Opportunity For Broad SMA Label
Keeping Track: Submissions For Dupilumab, Nusinersen; AbbVie Finds Breakthrough Space In Hep C
Stockwatch: Teva, Biogen, Ionis, Sage And The Art Of Strategic News Placement
Deal Watch: Roche Aborts But Regeneron, Amgen and Pfizer Sign Up
Merck, Allergan Suggested As Suitors But Biogen's Attractiveness Under Question
Trophos to file olesoxime after positive data in orphan indication

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097042

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel